Addex shareholders approve all resolutions at annual general meeting

Ad hoc announcement pursuant to art. 53 lr  geneva, switzerland, june 25, 2025 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 annual general meeting (agm).
ADXN Ratings Summary
ADXN Quant Ranking